Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $1.80 billion. The enterprise value is $1.48 billion.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 110.54 million shares outstanding. The number of shares has increased by 38.78% in one year.
| Current Share Class | 110.54M |
| Shares Outstanding | 110.54M |
| Shares Change (YoY) | +38.78% |
| Shares Change (QoQ) | +17.69% |
| Owned by Insiders (%) | 6.76% |
| Owned by Institutions (%) | 85.67% |
| Float | 82.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.08 |
| P/TBV Ratio | 5.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.27, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.27 |
| Quick Ratio | 13.98 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.59% and return on invested capital (ROIC) is -40.09%.
| Return on Equity (ROE) | -61.59% |
| Return on Assets (ROA) | -36.41% |
| Return on Invested Capital (ROIC) | -40.09% |
| Return on Capital Employed (ROCE) | -49.46% |
| Weighted Average Cost of Capital (WACC) | 3.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.06M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $46,000 in taxes.
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +204.29% in the last 52 weeks. The beta is -0.21, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | +204.29% |
| 50-Day Moving Average | 15.17 |
| 200-Day Moving Average | 12.97 |
| Relative Strength Index (RSI) | 50.74 |
| Average Volume (20 Days) | 1,114,869 |
Short Selling Information
The latest short interest is 14.83 million, so 13.42% of the outstanding shares have been sold short.
| Short Interest | 14.83M |
| Short Previous Month | 14.23M |
| Short % of Shares Out | 13.42% |
| Short % of Float | 17.89% |
| Short Ratio (days to cover) | 13.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | -90.40M |
| Operating Income | -153.29M |
| Pretax Income | -144.69M |
| Net Income | -144.74M |
| EBITDA | -152.77M |
| EBIT | -153.29M |
| Earnings Per Share (EPS) | -$1.53 |
Full Income StatementBalance Sheet
The company has $316.98 million in cash and $5.96 million in debt, giving a net cash position of $311.02 million or $2.81 per share.
| Cash & Cash Equivalents | 316.98M |
| Total Debt | 5.96M |
| Net Cash | 311.02M |
| Net Cash Per Share | $2.81 |
| Equity (Book Value) | 305.26M |
| Book Value Per Share | 2.78 |
| Working Capital | 300.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$123.34 million and capital expenditures -$138,000, giving a free cash flow of -$123.48 million.
| Operating Cash Flow | -123.34M |
| Capital Expenditures | -138,000 |
| Depreciation & Amortization | 525,000 |
| Net Borrowing | 256.31M |
| Free Cash Flow | -123.48M |
| FCF Per Share | -$1.12 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |